Andrew Kramer, a correspondent in the Moscow bureau of The New York Times, was vaccinated with a Russian vaccine against the Sputnik V coronavirus A piece in which the author describes how he received his first dose of the drug was published Saturday in the print version of the publication.
By the author’s own admission, he was initially skeptical about the Russian vaccine. His doubts were based primarily on the timing of the registration of the drug, which was announced: “even before the late stages of trials began.” But later, as The New York Times correspondent notes, he became convinced of the safety of the vaccine, which demonstrated “good results” and high efficacy at the end of the trials. Kramer called such indicators “a real achievement of Russian scientists.
At the same time, the author notes, the fact that over a million Russians have already been vaccinated with it, and supplies of the drug “to Belarus, Argentina, and other countries” confirm its safety. According to Kramer, “if dangerous side effects had been identified during the trials, they would have been known by now.
In addition to the results of clinical trials of the drug, another factor in favor of vaccination for Kramer was its affordability. The author notes that in Russia, unlike “the U.S. and other countries,” it was possible to avoid “queues and confusion” at vaccination centers.
Together, this prompted the New York Times journalist to make an appointment to be vaccinated – the first dose of the drug was administered to him in Moscow’s Polyclinic No. 5 last Monday. The author notes that he was able to avoid some of the side effects typical of the coronavirus vaccine, such as headaches and fever. After administering the drug, doctors asked the journalist to spend half an hour in the corridor of the clinic in case he went into anaphylactic shock, “which, fortunately, never happened.”
Russia was the first country in the world to register a coronavirus vaccine, dubbed Sputnik V, on August 11, 2020